ANIK — Anika Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $378.81m
- $305.95m
- $166.66m
- 78
- 36
- 88
- 74
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 115 | 130 | 148 | 156 | 167 |
Cost of Revenue | |||||
Gross Profit | 85.9 | 69 | 82.9 | 93.6 | 103 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 80.4 | 159 | 145 | 176 | 254 |
Operating Profit | 34.2 | -28.3 | 2.62 | -19.4 | -87.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 36.1 | -28.6 | 2.43 | -18.7 | -85.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | 27.2 | -24 | 4.13 | -14.9 | -82.7 |
Net Income Before Extraordinary Items | |||||
Net Income | 27.2 | -24 | 4.13 | -14.9 | -82.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 27.2 | -24 | 4.13 | -14.9 | -82.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.89 | 0.257 | 0.57 | -1.02 | -2.88 |